Article info
PDFClinical science
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
- Correspondence to Dr Irmela Mantel, Department of Ophthalmology, University Eye Hospital Jules Gonin, 15 Av. de France, Case postale 133, CH-1000 Lausanne 7, Switzerland; irmela.mantel{at}fa2.ch
Citation
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
Publication history
- Received October 30, 2013
- Revised February 19, 2014
- Accepted March 20, 2014
- First published April 10, 2014.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/